AU2004224332A1 - Esterified fatty acid composition - Google Patents

Esterified fatty acid composition Download PDF

Info

Publication number
AU2004224332A1
AU2004224332A1 AU2004224332A AU2004224332A AU2004224332A1 AU 2004224332 A1 AU2004224332 A1 AU 2004224332A1 AU 2004224332 A AU2004224332 A AU 2004224332A AU 2004224332 A AU2004224332 A AU 2004224332A AU 2004224332 A1 AU2004224332 A1 AU 2004224332A1
Authority
AU
Australia
Prior art keywords
composition
acid
fatty acid
administered
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004224332A
Other languages
English (en)
Inventor
Patrick S. Millsap
William P. Spencer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imagenetix Inc
Original Assignee
Imagenetix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33098072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004224332(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imagenetix Inc filed Critical Imagenetix Inc
Publication of AU2004224332A1 publication Critical patent/AU2004224332A1/en
Priority to AU2010202187A priority Critical patent/AU2010202187A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2004224332A 2003-03-20 2004-03-22 Esterified fatty acid composition Abandoned AU2004224332A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010202187A AU2010202187A1 (en) 2003-03-20 2010-05-28 Esterified fatty acid composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45586003P 2003-03-20 2003-03-20
US60/455,860 2003-03-20
PCT/US2004/008650 WO2004084829A2 (en) 2003-03-20 2004-03-22 Esterified fatty acid composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010202187A Division AU2010202187A1 (en) 2003-03-20 2010-05-28 Esterified fatty acid composition

Publications (1)

Publication Number Publication Date
AU2004224332A1 true AU2004224332A1 (en) 2004-10-07

Family

ID=33098072

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004224332A Abandoned AU2004224332A1 (en) 2003-03-20 2004-03-22 Esterified fatty acid composition
AU2010202187A Abandoned AU2010202187A1 (en) 2003-03-20 2010-05-28 Esterified fatty acid composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010202187A Abandoned AU2010202187A1 (en) 2003-03-20 2010-05-28 Esterified fatty acid composition

Country Status (6)

Country Link
US (1) US7612111B2 (enExample)
EP (1) EP1617830A4 (enExample)
JP (1) JP2006520803A (enExample)
AU (2) AU2004224332A1 (enExample)
CA (1) CA2519278C (enExample)
WO (1) WO2004084829A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776914B2 (en) * 2004-03-22 2010-08-17 Imagenetix, Inc. Esterified fatty acid composition
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
JP2011508047A (ja) * 2007-12-27 2011-03-10 サイバス，エルエルシー アルキルエステル脂肪酸配合物およびその用途
KR20110007088A (ko) * 2008-01-25 2011-01-21 비 앤드 티 에스.알.엘. 화장품 분야에서의 트랜스에스테르화 올리브 오일의 용도
WO2010005004A1 (ja) * 2008-07-07 2010-01-14 花王株式会社 キサンチンオキシダーゼ阻害剤及び尿酸生成阻害剤
US9925162B2 (en) * 2009-04-09 2018-03-27 The Regents Of The University Of Colorado Methods and compositions for inducing physiological hypertrophy
US20120142776A1 (en) * 2009-04-09 2012-06-07 Leinwand Leslie A Methods and compositions for inducing physiological hypertrophy
RU2012138047A (ru) * 2010-03-02 2014-04-10 Имадженетикс, Инк. Композиции, содержащие миристиновую кислоту, и их применения
ES2395539B1 (es) * 2011-06-16 2014-01-20 Agencia Pública Empresarial Sanitaria Hospital Alto Guadalquivir Uso del aceite de oliva en la prevención y el tratamiento de las enfermedades que cursan con un proceso isquémico
ITMI20130354A1 (it) * 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
DK3097910T3 (da) * 2014-01-24 2020-07-27 Univ Kyoto Antiinflamatorisk middel indeholdende sjælden fedtsyre
AU2016219974A1 (en) * 2015-02-18 2017-09-07 Tersus Life Sciences, LLC Methods for improving joint function
ITUB20153130A1 (it) * 2015-08-14 2017-02-14 Pharmanutra S P A Acidi grassi cetilati, impianto per la loro preparazione e relativo uso
CA3041829A1 (en) * 2016-10-31 2018-05-03 The Cleveland Clinic Foundation Capric acid and myristic acid compositions for treating conditions
IT201700089258A1 (it) 2017-08-02 2019-02-02 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di carenza di ferro
WO2020225946A1 (ja) * 2019-05-09 2020-11-12 株式会社島津製作所 試料の評価方法、分析方法、劣化試料の検出方法、劣化血漿試料検出用マーカーおよび劣化血清試料検出用マーカー
IT201900007326A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari
IT201900007311A1 (it) 2019-05-27 2020-11-27 Alesco Srl Procedimento per la preparazione di una composizione comprendente acidi grassi cetilati
IT201900007329A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati per uso nel trattamento della mucosa gastrica, diabete e alti livelli di glicemia
IT202300004227A1 (it) 2023-03-07 2024-09-07 Pharmanutra S P A Composizioni comprendenti acidi grassi cetilati e vitamina d, e loro usi relativi

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049824A (en) * 1976-05-03 1977-09-20 Harry Weldon Diehl Cetyl myristoleate
US4330557A (en) * 1979-05-21 1982-05-18 Claudio Cavazza Acyl-carnitine and use thereof in parenteral administration of triglycerides
US4454159A (en) * 1981-12-28 1984-06-12 Albert Musher Dermatological treatment preparations
JPS60215624A (ja) * 1984-04-11 1985-10-29 Akira Kitano 消炎鎮痛剤
JPS6172715A (ja) * 1984-09-18 1986-04-14 Kao Corp 外用抗炎症剤
JP2530661B2 (ja) * 1987-07-31 1996-09-04 ピジョン株式会社 乳液状皮膚清拭剤
JPH0423298Y2 (enExample) 1987-08-19 1992-05-29
JPH06247852A (ja) * 1993-02-22 1994-09-06 Sekisui Chem Co Ltd 炎症性皮膚疾患治療用外用剤
US5569676A (en) * 1995-05-24 1996-10-29 Diehl; Harry W. Method for the treatment of osteoarthritis
US6022551A (en) * 1998-01-20 2000-02-08 Ethicon, Inc. Antimicrobial composition
MXPA00010103A (es) * 1998-04-16 2002-08-06 Natural Health Products Intern Metodo para el tratamiento de asma.
US6417227B1 (en) * 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
GB9927629D0 (en) * 1999-11-24 2000-01-19 Croda Int Plc Compounds
EP1282412B1 (en) * 2000-05-12 2008-01-16 Meracol Corporation Limited Treating irritable bowel syndrome or disease
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation

Also Published As

Publication number Publication date
EP1617830A2 (en) 2006-01-25
CA2519278A1 (en) 2004-10-07
US7612111B2 (en) 2009-11-03
CA2519278C (en) 2012-06-05
WO2004084829A2 (en) 2004-10-07
EP1617830A4 (en) 2008-09-24
AU2010202187A1 (en) 2010-06-17
US20050208162A1 (en) 2005-09-22
WO2004084829A3 (en) 2005-01-27
JP2006520803A (ja) 2006-09-14

Similar Documents

Publication Publication Date Title
AU2010202187A1 (en) Esterified fatty acid composition
JP5662492B2 (ja) 抗炎症製剤
JP2023100869A (ja) 対象におけるマイトファジーを改善するための方法
JP5667737B2 (ja) イヌ変形性関節症食餌製剤
JP7761372B2 (ja) 対象におけるマイトファジーを改善するための方法
JP2015091817A (ja) イヌにおける軟骨損傷を軽減するための方法
JP2021521277A (ja) 動物における疼痛の処置のためのアサ抽出物
SK82699A3 (en) Use of glucocorticoids having a minimal systemic effect in the manufacture of a medicament
US7776914B2 (en) Esterified fatty acid composition
Mavrogenis et al. The effect of essential fatty acids and antioxidants combined with physiotherapy treatment in recreational athletes with chronic tendon disorders: a randomised, double-blind, placebo-controlled study
CN101653436B (zh) 用于治疗犬骨关节炎的ω‑3脂肪酸
EP1227826B1 (en) Composition comprising an extract of perna canaliculus, methylsulfonylmethane and glucosamine and use thereof
US20140356466A1 (en) Method for treating pain and inflammation associated with arthritis using chromium-three cation in combination with phyllanthus emblica and shilajit
CN1917869A (zh) 用于软骨感染病症的组合物和方法
AU2015372438B9 (en) Formulation and method of use
WO2024128457A1 (ko) 폴리뉴클레오티드나트륨을 포함하는 개 또는 고양이의 관절강 주입용 조성물
CN118806879A (zh) 一种具有骨关节保健作用的组合物及其应用

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted